This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
marijuana: Archive
Buy Aurora Cannabis (ACB) Stock Before Earnings, Despite Marijuana Volatility?
by Benjamin Rains
Despite growing sales and wider legalization, many pot stocks have been insanely volatile as Wall Street and investors try to wrap their heads around the marijuana industry. So should you think about buying "cheap" Aurora Cannabis (ACB) Stock before Q4 earnings?
TAPPositive Net Change STZPositive Net Change GWPHPositive Net Change SMGPositive Net Change MOPositive Net Change IIPRPositive Net Change ACBPositive Net Change TLRYPositive Net Change CGCNegative Net Change CRONNegative Net Change MJNegative Net Change
earnings marijuana
Best and Worst Performing ETFs of Last Week
by Sweta Killa
Wall Street recorded back-to-back weekly gains on optimism around U.S.-China trade relations.
RINGNegative Net Change VXXNegative Net Change ENZLPositive Net Change CHIKNo Net Change SILJNegative Net Change
etfs gold marijuana tech-stocks
Aurora Cannabis (ACB) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Cannabis revenue growth and improved gross margin are likely to aid Aurora Cannabis (ACB) in Q4 earnings.
ISRGNegative Net Change BAXPositive Net Change CNMDPositive Net Change ACBPositive Net Change
marijuana medical
5 ETFs Surge With Wall Street on Trade Talk Hopes
by Sweta Killa
We have highlighted five ETFs that gained most with the Wall Street rebound on Sep 5.
COPXPositive Net Change SOXXNegative Net Change XRTPositive Net Change PSCEPositive Net Change MJNegative Net Change
energy etfs marijuana retail semiconductor
What's in Store for Aurora Cannabis (ACB) in Q4 Earnings?
by Zacks Equity Research
Aurora Cannabis (ACB) expects revenues within $100-$107 million in fiscal Q4.
BAXPositive Net Change CNMDPositive Net Change ACBPositive Net Change CGCNegative Net Change
marijuana medical
Will Opioid Litigation Take its Toll on Pharma Companies?
by Indrajit Bandyopadhyay
Thousands of pending opioid-abuse lawsuits against several pharma companies come into limelight after the Oklahoma ruling against J&J. Let's see what's in store for these companies.
JNJNegative Net Change AGNPositive Net Change ENDPPositive Net Change TEVANegative Net Change MNKPositive Net Change
biotechs marijuana medical pharmaceuticals pot-stocks
Altria and Phillip Morris International in Merger Talks: What you Need to Know
by Mitchell Moore
On Tuesday, tobacco giants Altria (MO) and Philip Morris International (PM) announced discussions of a possible merger. The two companies stated that a deal has not yet been reached, but that it is possible and talks are underway.
MOPositive Net Change PMPositive Net Change CRONNegative Net Change
consumer-staples marijuana
ETF Winners & Losers of Last Week
by Sweta Killa
We have highlighted last week's best and worst performing ETFs.
ZROZNegative Net Change CQQQNegative Net Change ARGTPositive Net Change MJNegative Net Change DOGSNegative Net Change BDRYNegative Net Change
emerging-markets etfs marijuana tech-stocks
Bull of the Day: GW Pharmaceuticals (GWPH)
by Kevin Cook
A success story in cannabis medicine, 20 years in the making, is now rapidly growing sales to blockbuster status
GWPHPositive Net Change
cannabis marijuana medical pharmaceuticals
Canopy Growth (CGC) Earnings After The Bell: How High Can They Go?
by Daniel Laboe
Canopy is the clear leader in the marijuana space with a vastly diversified portfolio of cannabis products along with its STZ partnership.
ACBPositive Net Change CRONNegative Net Change CGCNegative Net Change TLRYPositive Net Change
earnings marijuana